{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:28:39Z","timestamp":1780590519690,"version":"3.54.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a common autoimmune disease. Tuberous sclerosis complex(TSC) is a rare autosomal dominant disorder. We report a case of RA with TSC. The patient was a 46-year-old woman with polyarthritis and cough symptoms, rheumatoid arthritis associated interstitial lung disease (RA-ILD) was initially considered, and after more than 3 months of anti-rheumatic treatment, the patient still had cough, and further examination revealed that the patient had lymphangioleiomyomatosis in the lungs, hepatic and renal angiomyolipomas, multiple subependymal nodules, Vertebral osteosclerotic nodules, as well as facial angiofibromas and periungual fibroma, RA was finally diagnosed with TSC, and everolimus 10mg qd was added to anti-rheumatic therapy for 1 month, and the patient\u2019s cough symptoms were relieved.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1425988","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:27:58Z","timestamp":1727324878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence"],"prefix":"10.3389","volume":"15","author":[{"given":"Hai-Qin","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-sheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0059-6","article-title":"Renal disease in tuberous sclerosis complex: pathogenesis and therapy","volume":"14","author":"Lam","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102373","DOI":"10.1016\/j.jaut.2019.102373","article-title":"The immunobiology of mTOR in autoimmunity","volume":"110","author":"Suto","year":"2020","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108793","DOI":"10.1016\/j.clim.2021.108793","article-title":"Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis","volume":"230","author":"Liu","year":"2021","journal-title":"Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000687","article-title":"Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases","volume":"32","author":"Wyman","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mtor (Mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.09.022","article-title":"Advances in systemic lupus erythematosus pathogenesis via mTOR signaling path way","volume":"50","author":"He","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58709","article-title":"Lymphangioleiomyomatosis- A wolf in sheep\u2019s clothing","volume":"122","author":"Henske","year":"2012","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212776","article-title":"Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis","volume":"14","author":"Hirose","year":"2019","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp398","article-title":"Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1","volume":"18","author":"Zhou","year":"2009","journal-title":"Hum Mol Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014121264","article-title":"Blocking rpS6 phosphorylation exacerbates Tsc1 deletion-induced kidney growth","volume":"27","author":"Wu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.03.035","article-title":"Tuberous sclerosis 1 (Tsc1) mediated mTORC1 activation promotes glycolysis in tubular epithelial cells in kidney fibrosis","volume":"98","author":"Cao","year":"2020","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96342","article-title":"Tuberous sclerosis complex\u2013associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt","volume":"128","author":"Zordan","year":"2018","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3877\/cma.j.issn.1674-6902.2023.03.008","article-title":"Five cases of pulmonary lymphangileiomyomatosis and  literature review","volume":"16","author":"Tiantian","year":"2023","journal-title":"Chin J Lung Dis (Electronic edition)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long- term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the m TOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"Mac Keigan","year":"2015","journal-title":"Neuro Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3806-1","article-title":"The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma","volume":"33","author":"Bissler","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005637","article-title":"Mosaic and intronic mutations in TSC1\/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing","volume":"11","author":"Tyburczy","year":"2015","journal-title":"PloS Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7684352","DOI":"10.1155\/2019\/7684352","article-title":"Low-dose sirolimus immunoregulation therapy in patients with active rheumatoid arthritis: A 24-week follow-up of the randomized, open-label,Parallel-controlled trial","volume":"2019","author":"Wen","year":"2019","journal-title":"J Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","article-title":"Low dose of il-2 combined with rapamycin restores and maintains the long-term balance of th17\/treg cells in refractory sle patients","volume":"20","author":"Zhao","year":"2019","journal-title":"BMC Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre,randomised,double-blind,placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1038\/s41598-019-49814-6","article-title":"Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy","volume":"9","author":"Ni","year":"2019","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/iju.2016.23.issue-10","article-title":"Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan","volume":"23","author":"Hatano","year":"2016","journal-title":"Int J Urol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1425988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:28:01Z","timestamp":1727324881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1425988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2024.1425988"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1425988","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"article-number":"1425988"}}